Sai Parenterals to Acquire Majority Stake in Bion Therapeutics’ Prescription Business
Hyderabad, November 16, 2026: Sai Parenterals Limited has signed a definitive agreement, through its wholly owned subsidiary SP Analytics Private Limited, to acquire a majority stake in Hyderabad-based Bion Therapeutics India Private Limited. The proposed all-cash acquisition is expected to be completed before the end of November 2026. Following the completion of the transaction, Bion Therapeutics will become a step-down subsidiary of Sai Parenterals.
The acquisition will strengthen Sai Parenterals’ presence in India’s branded prescription pharmaceutical market by adding 16 established brands, an experienced field force of approximately 250 employees, and an extensive distribution network. Founded in 2005, Bion Therapeutics operates across 12 states, with a strong presence in South, East and Northeast India. Its product portfolio focuses on specialised therapeutic segments, including neuropathy, diabetes supportive care, mitochondrial health, wound care and pain management. Its key brands include Meaxon, MITOQ7, Adgaba, Sunlite and LG Bion.
Bion has established strong relationships with approximately 20,000 doctors and a distribution network covering more than 17,000 retailers. The company follows a doctor-focused business model, building its brands through direct engagement with medical professionals across different specialties. These established relationships and its experienced field team are expected to provide Sai Parenterals with an immediate commercial platform to expand its reach in the domestic prescription market.
The acquisition is also expected to create significant operational synergies between the two companies. Bion’s products, currently manufactured through contract manufacturing partners, will progressively be shifted to Sai Parenterals’ own manufacturing facilities, which hold TGA-Australia and WHO-GMP accreditations. This transition is expected to strengthen quality control, ensure consistent product availability, improve supply chain efficiency and enhance operating margins.
Sai Parenterals also plans to leverage its research and development capabilities and its Australian and New Zealand-based Noumed platform to expand Bion’s product portfolio. Selected molecules from Noumed’s library of more than 511 TGA-approved dossiers could be introduced into the Indian market under Bion brands, subject to the necessary Indian regulatory approvals. In addition, the upcoming SAICRITI critical-care injectable facility at Gummadidala, expected to be completed in August 2027, is expected to support the expansion of Bion’s injectable product portfolio, including its flagship brand Meaxon.
Commenting on the agreement, Mr. Anil Kumar Karusala, Chairman and Managing Director of Sai Parenterals Limited, said that the acquisition would bring together Bion’s established doctor relationships and strong prescription brands with Sai Parenterals’ manufacturing infrastructure, research capabilities and product development pipeline. He added that the partnership would help expand the company’s presence in the Indian branded formulations market while creating opportunities for both businesses.
Mr. Laxman Prasad Shukla, Managing Director of Bion Therapeutics India Private Limited, said that joining the Sai Parenterals Group would provide the company with access to greater manufacturing capabilities and a wider product development pipeline. He stated that Bion’s existing management team would continue to lead the business, maintaining its established relationships with doctors and the medical community while expanding its product offerings.
The transaction will be funded through a combination of internal accruals, debt and a portion of the general corporate purposes allocation from Sai Parenterals’ initial public offering proceeds. Further details of the transaction will be disclosed at the appropriate stage.
